WHY REMDESIVIR WILL WORK DIFFERENTLY FOR COVID-19
Ebola causes systemic intravascular coagulation, which could have restricted remdesivir circulation through organs. The stronger efficacy of the Ebola targeting antibodies could be attributed to their ability to enter the lymphatic system, circumventing the coagulated capillaries - the antibodies could reach infected cells, whereas remdesivir could not.
Gilead is using the same remdesivir dosage in the COVID-19 trials as used in the Ebola trial. Fortunately, COVID-19 infected patients do not have circulatory problems.
Also, COVID-19 targets the lungs, and remdesivir robustly inhibits COVID-19 replication in human airway epithelial cells in vitro. The selected trial dosage is based on the effective in vitro inhibitory concentration along with in vivo pharmacokinetics and toxicity data. Accordingly, lung epithelial cells of COVID-19 infected patients receive an effective concentration of remdesivir.
Remdesivir may also be more readily incorporated into coronavirus RNA than Ebola RNA since remdesivir appears to have a higher affinity for the coronavirus polymerase than the Ebola polymerase.
There is a balm in Gilead?
I suspect some of the posters here were/are Gilead trolls or board members.
Kriggerel wrote:
“There is a balm in Gilead?”
That is what pops into my mind every time I see that company name.
REMDESIVIR is a trade mark drug, cost of treatment hundreds of dollars (to recover development costs). It can’t recover costs on the original intent of the drug, so they’re throwing it at COVID-19 to see relative effectiveness.
The HCQ-ZPak w/ zinc is closer to $20.
Follow the money ....
I will NEVER take this drug.
Ive also seen Kaletra mentioned as possibly useful to fight Wuhan-19. It is a combination of two antivirals.